[Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study].

Xu, Y; Shen, X X; Jin, Y Y; Li, J Y; Chen, L J; Zhang, R

Xu, Y; Shen, X X; Jin, Y Y; Li, J Y; Chen, L J; Zhang, R.

Afiliação

Xu Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Shen XX; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Jin YY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Li JY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Chen LJ; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Zhang R; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.

Zhonghua Xue Ye Xue Za Zhi ; 44(9): 749-754, 2023 Sep 14.

Article em Zh | MEDLINE | ID: mdl-38049319

Assuntos

Mieloma Múltiplo; Humanos; Prognóstico; Mieloma Múltiplo/diagnóstico; Hibridização in Situ Fluorescente; Estadiamento de Neoplasias; Estudos Retrospectivos

Palavras-chave

Mayo staging system; Multiple myeloma; Prognosis; R2-ISS

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Limite: Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google